14 completed, 4 unknown, 2 recruiting, 2 withdrawn. 23 Phase 2, 4 Phase 1, 4 Phase 3.
Follow Vulvovaginitis: new trials by email Literature Review of Vulvovaginitis trials Research Report on Vulvovaginitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4 - Vulvovaginal Candidiasis | Phase 2 | Withdrawn | EMS | 2022-07-01 | 2022-08-10 | |
| A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Chlorhexidine Gluconate, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Unknown | Karolinska Institutet | 60 | 2022-04-27 | 2022-05-20 |
| Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Oral Encochleated Amphotericin B (CAMB) - Vulvovaginal Candidiases, Yeast Infection | Phase 2 | Withdrawn | Matinas BioPharma Nanotechnologies, Inc. | 2019-12-01 | 2019-03-08 | |
| A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis | Phase 2 / Phase 3 | Unknown | ProFem GmbH | 432 | 2019-10-01 | 2022-09-22 |
| Patients With Vulvovaginal Candidiasis EPP-AF Gel 1%, EPP-AF Gel 2%, Clotrimazole - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | University of Sao Paulo | 90 | 2018-01-30 | 2018-10-19 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 137 | 2016-11-01 | 2018-11-02 |
| TOL-463 Phase 2 Study for Vaginitis TOL-463 - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 2 | Completed | Toltec Pharmaceuticals, LLC | 106 | 2016-07-15 | 2018-03-09 |
| RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%) - Candidiasis, Vulvovaginal, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 126 | 2016-06-08 | 2020-08-31 |
| Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis SCY-078, Fluconazole - Vulvovaginal Candidiasis | Phase 2 | Completed | Scynexis, Inc. | 96 | 2015-11-01 | 2019-07-12 |
| A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) VT-1161, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 2 | Completed | Viamet | 254 | 2015-02-10 | 2019-10-15 |
| Probiotic Implementation as Help in Solving Vaginal Infections Lactobacillus rhamnosus BMX 54 - Vaginal Infection, ASC-US | Phase 2 | Completed | University of Roma La Sapienza | 117 | 2015-02-01 | 2017-12-13 |
| A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) VT-1161, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Completed | Viamet | 55 | 2013-08-01 | 2018-08-01 |
| Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 188 | 2013-07-01 | 2018-07-18 |
Showing 20 of 23. Sign in to see all of them.
Candidiasis, Vulvovaginal (23) · Candidiasis (3) · Vaginitis (3) · Vaginosis, Bacterial (3) · Atypical Squamous Cells of the Cervix (1) · Mycoses (1) · Papillomavirus Infections (1) · Torulopsis (1) · Trichomonas Infections (1) · Vaginal Diseases (1)
Bacterial Infections and Mycoses (23) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Genital Diseases (23) · Genital Diseases, Female (23) · Infections (23) · Urogenital Diseases (23) · Vulvar Diseases (23) · Vulvitis (23) · Mycoses (22) · Vaginal Diseases (22) · Candidiasis (20) · Vaginitis (20) · Bacterial Infections (3)
Fluconazole (7) · Clotrimazole (3) · VT-1161 (2) · ibrexafungerp (2) · Lactulose (1) · Miconazole (1) · TOL-463 (1) · Vaccines (1) · butoconazole (1) · chlorhexidine gluconate (1) · occidiofungin (1)
Matinas BioPharma Nanotechnologies, Inc. (2) · ProFem GmbH (2) · Scynexis, Inc. (2) · Viamet (2) · AVVA Pharmaceuticals Ltd. (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · EMS (1) · Ferrer Internacional S.A. (1) · Karolinska Institutet (1) · LimmaTech Biologics AG (1) · MethylGene Inc. (1) · Min-Tze LIONG (1) · NEXBIOME THERAPEUTICS (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · NovaDigm Therapeutics, Inc. (1)
United States (11) · Austria (2) · Poland (2) · Belarus (1) · Belgium (1) · Brazil (1) · Dominican Republic (1) · India (1) · Kenya (1) · Malaysia (1) · Russia (1) · Slovakia (1) · Spain (1) · Sweden (1)
David Angulo, MD (2) · Alena Jandourek, MD (1) · Cathrin Alvendal, MD, PhD (1) · Christina Muzny, MD (1) · Douglas Kling (1) · Gregory Reid, MSc, MBA (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · Herbert Kiss, Prof. (1) · John P. Hennessey, Jr., Ph.D. (1) · Sumita Bhatia, MD (1)
PMID 36396498, PMID 29304768, PMID 29534874, PMID 29697768, PMID 30184181, PMID 32818963, PMID 34555149, PMID 40970688, PMID 41845293
2009 (1), 2023 (1)